Dr. Judith Currier

Dr. Currier is Professor of Medicine and Chief of the Division of Infectious Diseases and Co-Director of the Center for AIDS Research and Education Center (CARE) in the Department of Medicine at University of California, Los Angeles (UCLA). Since 2007 she has been Principal Investigator of the UCLA AIDS Prevention and Treatment Clinical Trials Unit. The UCLA CTU includes three sites involved in both prevention and treatment networks in Los Angeles and one in Brazil. In addition, she helps to oversee a large HIV treatment implementation program in Malawi.  She served as Vice Chair of the AIDS Clinical Trials Group Network from 2010-2017 and became Network Chair at the end of 2017.  Her research has focused on HIV Therapeutics, long-term complications of HIV disease with an emphasis on antiretroviral therapy, women’s health and cardiovascular disease.

Mark Feinberg

Lorem ipsum dolor sit amet, magna zril at pro, ex consul indoctum evertitur mei. Vix ad prompta tibique, veri nullam tritani qui in, graeci labitur nominavi mel ad. Mel eu debet audiam efficiantur, an vix imperdiet reprimique. Iudico euismod mandamus ne mel, at errem aliquip expetenda cum. Vim eu idque elitr everti, cu porro nobis similique cum, an cum paulo signiferumque.

Cum aperiam atomorum adipiscing an. Alii posse regione eam an, nibh voluptua gloriatur sea ne. Alii velit patrioque pro et, has debitis maiorum phaedrum te. Mea ei audiam feugait, ne enim aliquam per, cu nihil consequuntur sea. Cu sensibus dissentiet neglegentur ius, pri erat audiam evertitur no. Corpora persecuti nam te, vim ne case mazim efficiantur, pri eirmod vocibus ne. In zril singulis definiebas nam, no atomorum torquatos sea.

Vis cu dictas impedit explicari, et pro probo aperiam eloquentiam. Vim ea quidam aperiam, id nusquam nominavi sed. Quo an illud commodo, illud iriure in pri, ex eam latine scaevola. Legimus vulputate tincidunt pro ad, omnium utroque sit ei.

Jonathan Karn, Ph.D.

Dr. Karn is an internationally-recognized virologist who has made seminal contributions to the study of transcriptional control in HIV.  Between 1989 and 1993 Dr. Karn made the important discovery that the HIV regulatory proteins Tat and Rev are RNA binding proteins and demonstrated how this binding activity was essential for their biological activities. Recently, the Karn laboratory has established new model systems for studying HIV latency and demonstrated how epigenetic restrictions are used to silence HIV transcription. As part of a recent amfAR ARCHE study he demonstrated that estrogen receptor is a critical factor controlling HIV transcription. Dr. Karn is the Director of the CWRU/UH Center for AIDS Research since 2008. He served as a member of the NIAID Advisory Council and NIAID AIDS Research Advisory Council between 2011 and 2015 and appointed to the NCI Board of Scientific Counselors Basic Sciences for 2015-2020. He was a member of the NIH AMCB study section from 2003 to 2007, serving as Chairman from 2005-2007. He was a member of the ACTG Transformative Science Group (TSG) on HIV Cure strategies (2011-2015) and the Martin Delaney CARE Collaboratory. From 1987 to 1998 he played a leading role in the establishment and coordination of the UK’s research effort into AIDS as a member of the MRC AIDS Directed Program Steering Committee. Dr Karn is a member of the Case Comprehensive Cancer Center.  He was the Executive Editor of the Journal of Molecular Biology from 1989 to 2002 and is currently on the editorial board of Virology. Dr. Karn has mentored 8 graduate students, 32 postdoctoral fellows and 2 research associates since 1980.  The laboratory currently has 2 graduate students, 2 postdoctoral scholars, 5 research associates and 3 research assistants.  He was elected a Fellow of the American Society of Microbiology in 2011.

Daniel R. Kuritzkes, M.D.

Daniel R. Kuritzkes, MD received his BS and MS degrees in Molecular Biophysics and Biochemistry from Yale University, and his MD from Harvard Medical School.  He completed his clinical and research training in internal medicine and infectious diseases at Massachusetts General Hospital and was a visiting scientist at the Whitehead Institute for Biomedical Research before joining the faculty at the University of Colorado Health Sciences Center.  Dr. Kuritzkes returned to Harvard Medical School in 2002, where he is Professor of Medicine and Chief, Division of Infectious Diseases at Brigham and Women’s Hospital.

Dr. Kuritzkes has published extensively on antiretroviral therapy and drug resistance in HIV-1 infection.  He has chaired several multicenter studies of HIV therapy and previously chaired the AIDS Clinical Trials Group.  He has served on numerous NIH committees and currently is a member of the NIH Office of AIDS Research Advisory Council.  He is a former member of the Department of Health and Human Services panel on guidelines for antiretroviral therapy and a past Chair of the HIV Medicine Association Board of Directors.  He has been a member of several editorial boards, and serves as an Associate Editor of the Journal of Infectious Diseases.  His research interests focus on HIV therapeutics, antiretroviral drug resistance, and HIV eradication.

Jeff Lifson, M.D.

Dr. Lifson received his M.D. from Northwestern University Medical School in 1982, then pursued residency and research fellowship training in the Department of Pathology at the Stanford University School of Medicine. He became involved in AIDS-related research in 1983, playing a key role in establishing the first program in the United States to try to prevent transfusion-mediated transmission of AIDS through laboratory testing, while also conducting basic in vitro studies of AIDS pathogenesis. After several years of continuing research in AIDS pathogenesis while working in the biotechnology industry, during which time he helped pioneer the development and application of quantitative molecular methods for monitoring HIV replication in infected individuals, Dr. Lifson moved to the Frederick National Laboratory for Cancer Research in 1995, establishing the Retroviral Pathogenesis Section within the AIDS Vaccine Program. His work there has focused on the continuing development and application of quantitative virological and immunological methods for understanding retroviral pathogenesis and evaluating approaches for the prevention and treatment of retroviral infection and AIDS. In 2002, Dr. Lifson was named the director of the AIDS Vaccine Program, which became the AIDS and Cancer Virus Program in 2008.

https://ncifrederick.cancer.gov/Programs/Science/Acvp/Default.aspx – (ACVP webpage is currently under construction.)